IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - Feasibility and safety study
Huang, Xiao-Jun; Wang, Yu; Liu, Dai-Hong; Xu, Lan-Ping; Chen, Huan; Chen, Yu-Hong; Han, Wei; Shi, Hong-Xia; Liu, Kai-Yan
关键词Advanced Leukemia Donor Lymphocytes Infusion Granulocyte Colony-stimulating Factor Hematopoietic Stem Cell Transplantation
刊名JOURNAL OF CLINICAL IMMUNOLOGY
2008-07-01
DOI10.1007/s10875-008-9193-4
28期:4页:390-397
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Immunology
研究领域[WOS]Immunology
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; ACUTE MYELOID-LEUKEMIA ; COLONY-STIMULATING FACTOR ; BLOOD PROGENITOR CELLS ; CHEMOTHERAPY ; MALIGNANCIES ; REMISSION
英文摘要

Purpose We retrospectively evaluated the feasibility and safety of a modified prophylactic donor lymphocytes infusion (DLI) approach in advanced leukemia.

Materials and methods Thirty-three patients with advanced leukemia received modified prophylactic DLI; that is, granulocyte colony-stimulating factor-primed peripheral blood progenitor cells instead of steady-donor lymphocyte harvests were used, and a short-term immunosuppressive agent (cyclosporine A or methotrexate 10 mg once per week for 2 to 4 weeks) was used for prevention of DLI-associated graft versus host disease (GVHD) after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation.

Results Thirty-nine infusions were performed in 33 patients. The mononuclear cells and median CD3+ cells infused for DLI were 1-2x10(8) and 0.93x10(6) per kilogram, respectively. Six patients experienced II-IV-grade acute GVHD. Twenty patients developed chronic GVHD. No GVHD-related death or transfusion-related pancytopenia was observed. With an 18-month median follow-up, 16 patients were in disease-free survival, and overall survival at 1 and 1.5 years was 69.0% and 50.2%, respectively.

Conclusions The modified prophylactic DLI strategy might represent a step forward in the treatment of advanced leukemia.

语种英语
WOS记录号WOS:000257456500015
引用统计
被引频次:47[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55757
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Huang, Xiao-Jun,Wang, Yu,Liu, Dai-Hong,et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - Feasibility and safety study[J]. JOURNAL OF CLINICAL IMMUNOLOGY,2008,28(4):390-397.
APA Huang, Xiao-Jun.,Wang, Yu.,Liu, Dai-Hong.,Xu, Lan-Ping.,Chen, Huan.,...&Liu, Kai-Yan.(2008).Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - Feasibility and safety study.JOURNAL OF CLINICAL IMMUNOLOGY,28(4),390-397.
MLA Huang, Xiao-Jun,et al."Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - Feasibility and safety study".JOURNAL OF CLINICAL IMMUNOLOGY 28.4(2008):390-397.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Xiao-Jun]的文章
[Wang, Yu]的文章
[Liu, Dai-Hong]的文章
百度学术
百度学术中相似的文章
[Huang, Xiao-Jun]的文章
[Wang, Yu]的文章
[Liu, Dai-Hong]的文章
必应学术
必应学术中相似的文章
[Huang, Xiao-Jun]的文章
[Wang, Yu]的文章
[Liu, Dai-Hong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。